# Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL

> **NCT04862806** · NA · UNKNOWN · sponsor: **Bnai Zion Medical Center** · enrollment: 1000 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DIAGNOSTIC_TEST:** COVID-19 serology

## Key facts

- **NCT ID:** NCT04862806
- **Lead sponsor:** Bnai Zion Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-01
- **Primary completion:** 2021-09
- **Final completion:** 2022-03
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2021-09-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04862806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04862806, "Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT04862806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*